Literature DB >> 32114714

The unintended consequences of the 340B safety-net drug discount program.

Samuel Thomas1,2, Kevin Schulman3.   

Abstract

Mesh：

Substances：

Year:  2020        PMID： 32114714      PMCID： PMC7080379          DOI： 10.1111/1475-6773.13281

Source DB:  PubMed          Journal:  Health Serv Res        ISSN： 0017-9124            Impact factor:   3.402


× No keyword cloud information.
  10 in total

1.  Estimated Changes in Manufacturer and Health Care Organization Revenue Following List Price Reductions for Hepatitis C Treatments.

Authors:  Sean Dickson; Ian Reynolds
Journal:  JAMA Netw Open       Date:  2019-07-03

2.  The impact of specialty pharmaceuticals as drivers of health care costs.

Authors:  Bradford R Hirsch; Suresh Balu; Kevin A Schulman
Journal:  Health Aff (Millwood)       Date:  2014-10       Impact factor: 6.301

3.  Policy Statement on the 340B Drug Pricing Program by the American Society of Clinical Oncology.

Authors: 
Journal:  J Oncol Pract       Date:  2014-04-15       Impact factor: 3.840

4.  Consequences of the 340B Drug Pricing Program.

Authors:  Sunita Desai; J Michael McWilliams
Journal:  N Engl J Med       Date:  2018-01-24       Impact factor: 91.245

5.  Trends in hospital-physician integration in medical oncology.

Authors:  Jeffrey D Clough; Michaela A Dinan; Kevin A Schulman
Journal:  Am J Manag Care       Date:  2017-10       Impact factor: 2.229

6.  Impact of the 340B Drug Pricing Program on Cancer Care Site and Spending in Medicare.

Authors:  Jeah Jung; Wendy Y Xu; Yamini Kalidindi
Journal:  Health Serv Res       Date:  2018-01-22       Impact factor: 3.402

7.  US Spending on Personal Health Care and Public Health, 1996-2013.

Authors:  Joseph L Dieleman; Ranju Baral; Maxwell Birger; Anthony L Bui; Anne Bulchis; Abigail Chapin; Hannah Hamavid; Cody Horst; Elizabeth K Johnson; Jonathan Joseph; Rouselle Lavado; Liya Lomsadze; Alex Reynolds; Ellen Squires; Madeline Campbell; Brendan DeCenso; Daniel Dicker; Abraham D Flaxman; Rose Gabert; Tina Highfill; Mohsen Naghavi; Noelle Nightingale; Tara Templin; Martin I Tobias; Theo Vos; Christopher J L Murray
Journal:  JAMA       Date:  2016-12-27       Impact factor: 56.272

8.  The 340B drug discount program: hospitals generate profits by expanding to reach more affluent communities.

Authors:  Rena M Conti; Peter B Bach
Journal:  Health Aff (Millwood)       Date:  2014-10       Impact factor: 6.301

9.  Budgetary impact analysis of a primary care-based hepatitis C treatment program: Effects of 340B Drug Pricing Program.

Authors:  Eric A Jones; Benjamin P Linas; Ve Truong; James F Burgess; Karen E Lasser
Journal:  PLoS One       Date:  2019-03-14       Impact factor: 3.752

10.  Revenues and Profits From Medicare Patients in Hospitals Participating in the 340B Drug Discount Program, 2013-2016.

Authors:  Rena M Conti; Sayeh S Nikpay; Melinda B Buntin
Journal:  JAMA Netw Open       Date:  2019-10-02
  10 in total
  2 in total

1.  Spending For Orphan Indications Among Top-Selling Orphan Drugs Approved To Treat Common Diseases.

Authors:  Kao-Ping Chua; Lauren E Kimmel; Rena M Conti
Journal:  Health Aff (Millwood)       Date:  2021-03       Impact factor: 6.301

2.  Association of Beneficiary-Level Risk Factors and Hospital-Level Characteristics With Medicare Part B Drug Spending Differences Between 340B and Non-340B Hospitals.

Authors:  Yufei Li; Susan Xu
Journal:  JAMA Netw Open       Date:  2022-02-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.